多发性骨髓瘤15年无进展生存的决定因素;来自单一机构的现实世界数据
Meletios A Dimopoulos1,2, Ioannis Ntanasis-Stathopoulos1, Despina Fotiou1
1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
American journal of hematology
|July 19, 2025
概括
大约15%的多发性骨髓瘤患者接受初始疗法治疗,长期存活超过15年. 一个较小的群体,8%,保持长期缓解,没有维护,突出了不同的患者子组,具有有利的结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床医学 临床医学
背景情况:
- 多发性骨髓瘤由于治疗方面的进步,越来越多地被管理为慢性疾病.
- 确定具有特别有利结果的患者子组对于优化治疗策略至关重要.
研究的目的:
- 评估多发性骨髓瘤患者的临床和疾病特征,随访至少15年.
- 在前线治疗后识别具有非常长期存活率 (>15年) 和疾病缓解 (>15年) 的患者.
主要方法:
- 对323名连续,未经选择的多发性骨髓瘤患者的回顾性分析,这些患者在1994年至2009年期间被诊断出患有多发性骨髓瘤.
- 15年和20年累积生存率和无进展生存率 (PFS) 的评估.
- 确定与长期PFS相关的因素.
主要成果:
- 15年和20年累积存活率分别为18%和14%;49名患者存活了超过15年.
- 15年和20年的累积PFS率分别为9%和7%;25名患者 (8%) 实现了长期无进展生存.
- 年龄较小,表现良好状态,低/中等ISS,不存在不良细胞遗传学,自身移植和对初始治疗的完整反应 (CR) 与延长PFS相关.
结论:
- 大约15%的接受常规化疗或第一代新药治疗的患者实现长期存活 (>15年).
- 大约8%的患者在没有维持治疗的情况下保持长期缓解 (>15年).
- 在15年内以负的最小残留疾病达到完全反应,预示着持续的疾病状况.
相关概念视频
01:21Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
01:20Comparing the Survival Analysis of Two or More Groups
291
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
291
01:24Kaplan-Meier Approach
272
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
272
01:20Actuarial Approach
137
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
137